The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Lithium Intoxication
Abstract
Normally, lithium is not present in significant amounts in body fluids (<0.2 mEq/L). However, lithium salts have been used therapeutically for almost 150 years, beginning with its use for the treatment of gout (or urice acid diathesis) in the 1850s (1). Although gout was believed to include symptoms of mania and depression, it wasn't until the 1880s that John Aulde and Carl Lange observed that lithium could be used to treat symptoms associated with depression, independent of gout (1). However, the use of lithium became problematic and was discarded due to the serious toxicity associated with the widespread use of lithium in tonics, elixirs, and as a salt substitute (1). The modern era of lithium usage as a pharmacologic agent began with its “rediscovery” in 1950 by Cade and the clinical studies by Schou in the 1950s that established lithium as an effective treatment of manic-depressive illness (1). Lithium is now the drug of choice for treating bipolar affective disorders. It is successful in improving both the manic and depressive symptoms in 70 to 80% of patients (2). Lithium may also be used to treat alcoholism, schizoaffective disorders, and cluster headaches (3). Thus, lithium is an indispensable pharmaceutical component of modern psychiatric therapy. Unfortunately, lithium also has a narrow therapeutic index, with therapeutic levels between 0.6 and 1.5 mEq/L (Table 1) (2,3,4). The optimal steady-state concentration of lithium for maintenance treatment of bipolar disorders is generally considered to be 0.6 to 1.2 mEq/L, with slightly elevated steady-state concentrations (0.8 to 1.5 mEq/L) indicated for the acute management of manic episodes (5). Because toxicity can occur at levels >1.5 mEq/L, lithium levels must be carefully monitored and lithium dosage adjusted as necessary. This is especially true following changes in other medications that alter renal function, such as angiotensin-converting enzyme (ACE) inhibitors or nonsteroidal anti-inflammatory drugs (NSAID). Nephrologists require a thorough understanding of lithium since it is excreted by the kidney and its toxic side effects commonly affect renal function. In addition, the treatment of lithium intoxication usually requires consideration of the need for acute hemodialysis, a decision that should only be made by a nephrologist.Table 1: Lithium pharmacologyaPhysiology Lithium physiology has been studied extensively for almost 50 yr because of its use in treating manic-depressive illness. Lithium can substitute for sodium or potassium on several transport proteins that normally transport sodium or potassium, thus providing a pathway for lithium entry into cells. The pathways for transporting lithium out of cells are more limited, resulting in lithium accumulating intracellularly. It is important to realize that lithium does not equilibrate passively between intracellular and extracellular compartments. If lithium equilibrated passively across cell membranes, the lithium cell-to-plasma concentration ratio would be approximately 10 to 30 because of the negative membrane potential (-60 to -90 mV) of most cells. However, the measured cell-to-plasma lithium concentration ratio is actually much lower. For example, a ratio of 2 to 4 is found in rat vascular smooth muscle cells, rat brain slices, cultured neuroblastoma cells, and rat skeletal muscle cells (6). Thus, lithium must be actively transported out of most cells. Two of the major lithium transporting proteins are the sodium channel and the sodium—proton exchanger. Both transporters are inhibited by amiloride (1,6,7). The amiloride-sensitive sodium channel (ENaC) is a key transporter that is involved in sodium homeostasis in the collecting duct (Figure 1). This channel has approximately equal permeability to lithium and sodium (1,6,7) and is a major pathway for lithium accumulation in collecting duct cells.Figure 1: . Lithium transport pathways in proximal and distal tubule cells. (A) A schematic view of a proximal tubule cell is shown indicating putative apical and basolateral transport pathways for lithium. A transporter is indicated by a shaded oval buried in the membrane, with an arrow indicating the direction of lithium movement; however, an “X” adjacent to the arrow indicates that experimental evidence suggests that the transport pathway is unlikely for lithium. The apical transporters illustrated are the sodium—hydrogen exchanger (NHE), and two sodium-dependent cotransporters: The sodium—glucose shown with lithium and glucose moving on the transporter; the sodium-phosphate cotransporter with lithium and monohydrogen phosphate. However, the latter is not a likely pathway for lithium transport. The paracellular pathway is indicated as lithium movement through an intercellular junction. However, this is an unlikely pathway for lithium. The basolateral transporters illustrated are the sodium—potassium ATPase, which, as discussed in the text, is an unlikely lithium transport pathway and the puta
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lithium-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla.
Marples, D., Christensen, S., Christensen, E. I., Ottosen, P. D., & Nielsen, S. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117863 · Cited by 442
Prevalence, Pathogenesis, and Treatment of Renal Dysfunction Associated With Chronic Lithium Therapy
Boton, R., Gaviria, M., & Batlle, D. C. (1987) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(87)80098-7 · Cited by 353
Clinical manifestations and management of acute lithium intoxication
Okusa, M. D., & Crystal, L. J. T. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90308-5 · Cited by 213
Clinical Relevance of Drug Interactions with Lithium
Finley, P. R., Warner, M. D., & Peabody, C. A. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199529030-00004 · Cited by 210
BENDZ, H., SJÖDIN, I., TOSS, G., & BERGLUND, K. (1996) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1996.28864000.x · Cited by 144
Leblanc, M., Raymond, M., Bonnardeaux, A., Isenring, P., Pichette, V., Geadah, D., Ouimet, D., Ethier, J. H., & Cardinal, J. (1996) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(96)90359-5 · Cited by 79
Effects of Lithium Therapy on Bone Mineral Metabolism: A Two-Year Prospective Longitudinal Study
Mak, T. W. L. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.11.3857 · Cited by 66
Drug interactions and consequences of sodium restriction
Wm, B. (1997) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/65.2.678s · Cited by 57
Diazepam–omeprazole inhibition interaction: an in vitro investigation using human liver microsomes
Zomorodi, K., & Houston, J. B. (1996) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1996.03563.x · Cited by 37
Phosphate transport by the human renal cotransporter NaPi-3 expressed in HEK-293 cells
Timmer, R. T., & Gunn, R. B. (1998) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1998.274.3.c757 · Cited by 34
Self-citationIn vitro binding of lithium using the cation exchange resin sodium polystyrene sulfonate
Watling, S., Gehrke, J. C., Gehrke, C. W., Zumwalt, R. W., & Pribble, J. P. (1995) · The American Journal of Emergency Medicine · doi:10.1016/0735-6757(95)90202-3 · Cited by 30
Bosinski, T. J., Bailie, G. R., & Eisele, G. (1998) · The American Journal of Emergency Medicine · doi:10.1016/s0735-6757(98)90080-8 · Cited by 29
Emergency Treatment of Lithium-Induced Diabetes Insipidus with Nonsteroidal Anti-Inflammatory Drugs
Lam, S., & Kjellstrand, C. M. (1997) · Renal Failure · doi:10.3109/08860229709026274 · Cited by 24
Cited by
Global Lithium Sources—Industrial Use and Future in the Electric Vehicle Industry: A Review
Kavanagh, L., Keohane, J., Garcia Cabellos, G., Lloyd, A., & Cleary, J. (2018) · Resources · doi:10.3390/resources7030057 · Cited by 389
Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus
Bockenhauer, D., & Bichet, D. G. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.89 · Cited by 333
The recovery and separation of lithium by using solvent extraction methods
Kanagasundaram, T., Murphy, O., Haji, M. N., & Wilson, J. J. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.215727 · Cited by 263
(2011) · doi:10.2165/11586970-000000000-00000 · Cited by 225
Nielsen, J., Hoffert, J. D., Knepper, M. A., Agre, P., Nielsen, S., & Fenton, R. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800001105 · Cited by 109
Metadata
- Authors
- TIMMER, R. T., & SANDS, J. M.
- Venue
- Journal of the American Society of Nephrology
- Published
- 1999-03
- Volume
- 10
- Issue
- 3
- Pages
- 666-674
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W4248590234
- Cited by
- 360
- References
- 13
- FWCI
- 4.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.